Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin Sequential Therapy After Intensive Glycemic Control in Type 2 Diabetes Mellitus
ChiCTR2500106205Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Jilin University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Hospital of Jilin University. Primary endpoint: glycated hemoglobin at 12 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500106205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106205.